PhD, Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Basel-based biotech company NBE Therapeutics AG and SOTIO announced that the companies have entered into a collaboration for the development of next-generation antibody-drug conjugates (ADCs) for improved cancer therapy. Under the agreement, NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets.
The ADC products will be based on NBE’s proprietary antibody discovery and conjugation platforms, including NBE’s Transpo-mAbTM antibody platform, its site-specific SMACTM conjugation technology and its novel ultra-potent toxin platform, the press release states. SOTIO will have global responsibility for clinical development, registration and commercialization of the ADC products. As part of the deal, PPF Group (owner of SOTIO) has committed to invest CHF10m in the next financing round of NBE.
Upon exercise of the target options, NBE will be eligible for an option exercise fee, as well as milestone payments and royalties based on global net sales of the products. In addition, NBE will be reimbursed for its R&D expenses incurred in connection with the development of the product in collaboration with SOTIO.
NBE-Therapeutics is privately and was founded in 2012 with the vision of developing next-generation ADC products. The products will be advanced to clinical proof of concept with the goal of improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors
Complete press release by NBE Therapeutics